Actively Recruiting

Phase 3
Age: 18Years - 39Years
FEMALE
NCT06150703

Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles

Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-08-24

652

Participants Needed

1

Research Sites

169 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The development of stimulation protocols for in vitro fertilisation (IVF) has led to a paradox. It has now been established that obtaining a large number of oocytes is a key to success, but that it is also a risk factor for embryo transfer failure after puncture (disruption of endometrial receptivity due to luteal insufficiency) and a risk factor for complications such as ovarian hyperstimulation syndrome (OHSS).

CONDITIONS

Official Title

Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles

Who Can Participate

Age: 18Years - 39Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients requiring conventional IVF or IVF with sperm injection (ICSI) from the partner or donor under the conditions of management defined by French law
  • Patients aged 18 to 39 included
  • First or second attempt at IVF or ICSI for pregnancy
  • BMI < 35 kg/m2
  • Anti-Mullerian hormone (AMH) > 1 ng/ml (= 7 pmol/L) and/or antral follicle count ≥ 8 within the year prior to inclusion
  • AMH < 5 ng/ml and/or antral follicle count <40 within the year prior to inclusion
  • Treatment with recombinant FSH
  • Antagonist protocol (with pre-treatment or not)
  • Initial dose of recombinant FSH between 75 and 450 IU
  • Signed informed consent
  • Affiliation to the social security system (excluding AME)
Not Eligible

You will not qualify if you...

  • Patient diagnosed with HIV infection
  • ICSI with sperm from testicular biopsy
  • Pre-implantation diagnosis
  • Hypogonadotropic hypogonadism (amenorrhea or spaniomenorrhea with basal LH <1.2 IU/L)
  • History of severe ovarian hyperstimulation syndrome (OHSS)
  • Unoperated hydrosalpinx
  • Intracavitary polyps or myomas deforming the cavity
  • Known hypersensitivity to the investigational drugs and/or their excipients
  • Gynaecological bleeding or genital haemorrhage
  • History of epilepsy and/or intracranial tumors potentially causing epilepsy
  • Tumours of the hypothalamus or pituitary gland
  • Ovarian enlargement or cysts unrelated to polycystic ovary syndrome
  • Severe adenomyosis requiring a long protocol
  • Carcinoma of the ovary, uterus or breast
  • Active thromboembolic events
  • Severe impairment of liver function
  • Breastfeeding women
  • Patients under court protection, guardianship or curators
  • Current participation in another therapeutic interventional trial on the day of inclusion
  • Patients who do not speak or understand French

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Maeliss Peigné

Bondy, France

Actively Recruiting

Loading map...

Research Team

M

Maeliss Peigné, MCU-PH

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles | DecenTrialz